Drugs & Aging

, Volume 16, Issue 5, pp 351–364 | Cite as

Heparin-Induced Thrombocytopenia

Minimising the Risks in the Elderly Patient
  • Brigitte Tardy-Poncet
  • Bernard Tardy
Review Article


Heparin therapy may sometimes be seriously complicated by heparin-induced thrombocytopenia (HIT). Heparin use for treatment and prevention of thromboembolism is more common in the elderly and that may be the reason why HIT is reported more frequently in this group of patients. The first approach in the management of HIT is awareness of this disorder. The morbidity and mortality associated with HIT may be reduced by avoiding unnecessary heparin exposure, by reducing the duration of heparinisation and by using low molecular weight heparins rather than unfractionated heparin. A decrease from baseline values of at least 30% in the platelet count, any unexplained thrombotic event and the finding of a white clot at thrombectomy are clinical warning signs that should alert physicians to a possible diagnosis of HIT. Indeed, early clinical recognition of HIT may sometimes prevent the severe complications associated with this disorder. Objective confirmation of the diagnosis of HIT is difficult because none of the available biological tests possess 100% sensitivity or 100% specificity. It is, however, possible to optimise the performances of the functional assay, mainly the platelet aggregation test (PAT), by following the manoeuvres described by different investigators. The use of 2 classes of assay (functional and antigen assays) and repeat testing on another day can avoid misdiagnosis of HIT. An alternative parenteral anticoagulant treatment is most often mandatory after heparin withdrawal. Danaparoid sodium and lepirudin are 2 drugs that are currently available for the treatment of HIT, and the efficacy of argatroban needs to be confirmed in greater numbers of patients with HIT. The use of these drugs has contributed to the reduction in the mortality and morbidity associated with HIT.


  1. 1.
    Boon DMS, Kappers-Klunne MC, Michiels JJ, et al. Heparin-induced thrombocytopenia and thrombosis: a potential fatal complication in a routine treatment. Neth J Med 1995; 46: 146–52PubMedCrossRefGoogle Scholar
  2. 2.
    Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502–7PubMedCrossRefGoogle Scholar
  3. 3.
    Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56: 12–6PubMedCrossRefGoogle Scholar
  4. 4.
    Magnani HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia: proceedings of a workshop held in London, 1996 Nov 1. Platelets 1997; 8(1): 74–81Google Scholar
  5. 5.
    Tardy-Poncet B, Tardy B, Reynaud J, et al. Efficacy and safety of Orgaran (ORG 10172) in critically ill patients with heparin associated thrombocytopenia. Chest 1999; 115: 1616–20PubMedCrossRefGoogle Scholar
  6. 6.
    Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925–30PubMedGoogle Scholar
  7. 7.
    Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med 1989; 40: 31–44PubMedCrossRefGoogle Scholar
  8. 8.
    Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81–8PubMedCrossRefGoogle Scholar
  9. 9.
    Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247–51PubMedGoogle Scholar
  10. 10.
    Amiral J, Wolf M, Fischer AM, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-Pf4 complexes in patients with heparin-induced thrombocytopenia [letter]. Br J Haematol 1996; 92: 954PubMedCrossRefGoogle Scholar
  11. 11.
    Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Thromb Haemost 1995; 21: 106–16CrossRefGoogle Scholar
  12. 12.
    Warkentin TE, Hayward CPM, Bochkov LK. Sera from patients with heparin-induced thrombocytopenia generate platelet derived microparticles with pro-coagulant activity an explanation for the thrombotic complications of heparin-induced thrombocytopenia [abstract]. Blood 1994; 84: 3691PubMedGoogle Scholar
  13. 13.
    Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated-thrombocytopenia. N Engl J Med 1987; 316: 581–9PubMedCrossRefGoogle Scholar
  14. 14.
    Zalcberg JR, McGrath K, Dauer R, et al. Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation. Br J Haematol 1983; 54: 955–60CrossRefGoogle Scholar
  15. 15.
    Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991; 10: 1–34PubMedGoogle Scholar
  16. 16.
    Tardy-Poncet B, Tardy B, Grelac F, et al. Pentosan polysulph-ate-induced thrombocytopenia and thrombosis. Am J Hematol 1994; 45: 252–7PubMedCrossRefGoogle Scholar
  17. 17.
    Tardy B, Tardy-Poncet B, Zeni F, et al. Thrombocytopenia associated with low molecular weight heparin [letter]. Lancet 1991; 338: 1217Google Scholar
  18. 18.
    Doty JR, Alving BM, Mc Donnell DE, et al. Heparin-associated thrombocytopenia in the neurosurgical patient. Neurosurgery 1986; 19: 69–72PubMedCrossRefGoogle Scholar
  19. 19.
    Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431–9PubMedCrossRefGoogle Scholar
  20. 20.
    Hirsch J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetic, dosing considerations, monitoring, efficacy and safety. Chest 1995; 108 Suppl.: 258–75SCrossRefGoogle Scholar
  21. 21.
    Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330–5PubMedCrossRefGoogle Scholar
  22. 22.
    Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629–35PubMedCrossRefGoogle Scholar
  23. 23.
    Boskhov LK, Warkentin TE, Hayward CPM, et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322–8CrossRefGoogle Scholar
  24. 24.
    Belmain J, Trivalle C, Medjahed S, et al. Use of low molecular weight heparin in geriatric hospitals and institutions in France: a national one-day survey in 97 centers [abstract]. Haemostasis 1998; S2: 297Google Scholar
  25. 25.
    Gallus AS, Jackaman J, Tillett J, et al. Safety and efficiency of warfarin started early after submissive venous thrombosis or pulmonary embolism. Lancet 1986; II: 1293–6CrossRefGoogle Scholar
  26. 26.
    Chong BH. Heparin-induced thrombocytopenia. Aust N Z J Med 1992; 22: 145–52PubMedCrossRefGoogle Scholar
  27. 27.
    Erni J, Frey HR, Locher G. The heparin-induced thrombosis-thrombocytopenia syndrome. Dtsch Med Wochenschr 1987; 112: 801–5PubMedCrossRefGoogle Scholar
  28. 28.
    Ansell J, Deykin D. Heparin-induced thrombocytopenia and recurrent thromboembolism. Am J Hematol 1980; 8: 325–2PubMedCrossRefGoogle Scholar
  29. 29.
    Hach-Wunderle V, Kainer K, Krug B. Heparin-associated thrombosis despite normal platelet counts. Lancet 1994; 344: 469–70PubMedGoogle Scholar
  30. 30.
    Leroy J, Leclerc MH, Delahousse B. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216). Semin Thromb Haemost 1985; 11: 326–9CrossRefGoogle Scholar
  31. 31.
    Buge A, Poisson M, Vidhaillet M, et al. Thrombopenia and disseminated intravascular coagulation during treatment with heparin: two cases with neurological complications. Rev Neu-rol 1988; 144: 289–94Google Scholar
  32. 32.
    Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494–7PubMedCrossRefGoogle Scholar
  33. 33.
    Warkentin TE. Heparin-induced thrombocytopenia, heparin-induced skin lesions, and arterial thrombosis [abstract]. Thromb Haemost 1997; Suppl.: 562Google Scholar
  34. 34.
    Silver D, Kapsch D, Tsoi E. Heparin-induced thrombocytopenia, thrombosis and hemorrahge. Ann Surg 1983; 198: 301–6PubMedCrossRefGoogle Scholar
  35. 35.
    Laster J, Cikrit D, Walker N, et al. The heparin-induced throm-bocytopenia syndome: an update. Surgery 1987; 102: 763–8PubMedGoogle Scholar
  36. 36.
    Greinacher A, Amiral J, Dummel V. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test and platelet factor 4/heparin enzyme linked immunosorbent assay. Transfusion 1994; 34: 381–5PubMedCrossRefGoogle Scholar
  37. 37.
    Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27–30PubMedGoogle Scholar
  38. 38.
    Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344–50PubMedGoogle Scholar
  39. 39.
    Brandt J, Isenhart CE, Osborne JM. On the role of platelet FCγ IIA phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564–72PubMedGoogle Scholar
  40. 40.
    Lecompte T. Drug-dependent platelet activating IgG: heparin and streptokinase. In: Seghatchian MJ, Samama MM, Hecker SP, editors. Hypercoagulable states. New York (NY): CRC Press, 1996: 173–8Google Scholar
  41. 41.
    Isenhart CE, Brandt JT. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1993; 99: 324–30PubMedGoogle Scholar
  42. 42.
    Salem HH, van der Weyden MB. Heparin-induced thrombo-cytopenia: variable platelet rich plasma reactivity to heparin dependent aggregating factor. Pathology 1983; 15: 297–9PubMedCrossRefGoogle Scholar
  43. 43.
    Greinacher A, Michels I, Liebenhoff U, et al. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 1993; 84: 711–6PubMedCrossRefGoogle Scholar
  44. 44.
    Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64–73PubMedCrossRefGoogle Scholar
  45. 45.
    Greinacher A, Michels I, Kiefel V. Arapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734–6PubMedGoogle Scholar
  46. 46.
    Amiral J, Bridey F, Dreyfus M. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-in-duced thrombocytopenia. Thromb Haemost 1992; 68: 95–6PubMedGoogle Scholar
  47. 47.
    Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA with the 14C serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995; 104: 648–54PubMedGoogle Scholar
  48. 48.
    Amiral J, Marfaing-Koka A, Wolf M. Presence of auto-antibodies to interleukin 8 or neutrophil activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996; 88: 410–6PubMedGoogle Scholar
  49. 49.
    Amiral J. Diagnostic tests in heparin-induced thombocyto-penia: proceedings of a workshop held in London on 1 November 1996. Heparin-induced thrombocytopenia: an under-diagnosed syndrome? Platelets 1997; 8: 65–82CrossRefGoogle Scholar
  50. 50.
    Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S–510SPubMedCrossRefGoogle Scholar
  51. 51.
    Tardy B, Tardy-Poncet B, Fournel P, et al. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999; 82: 1199–200PubMedGoogle Scholar
  52. 52.
    Tardy-Poncet B, Mahul P, Beraud AM, et al. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome. Br J Haematol 1995; 90: 969–70CrossRefGoogle Scholar
  53. 53.
    Tardy B, Tardy-Poncet B, Viallon A. Fatal danaparoid sodium-induced thrombocytopenia and thromboses [letter]. Thromb Haemost 1998; 80: 530PubMedGoogle Scholar
  54. 54.
    Meuleman DG. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992; 22: 58–65PubMedGoogle Scholar
  55. 55.
    ten Cate H, Henny CP, ten Cate JW, et al. Anticoagulant effects of a low molecular weight heparinoid (Org10172) inhuman volunteers and haemodialysis patients. Thromb Res 1985; 38: 211–22CrossRefGoogle Scholar
  56. 56.
    ten Cate H, Lamping RJ, Henny CP, et al. Automated amidolytic method for determining heparin, a heparinoid and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem 1984; 30(6): 860–4PubMedGoogle Scholar
  57. 57.
    Bradbrook ID, Magnani HN, Moelker HC, et al. Org 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 1987; 23: 667–75PubMedCrossRefGoogle Scholar
  58. 58.
    Henny CP, ten Cate H, ten Cate JW, et al. Thrombosis prophylaxis in an ATIII deficient pregnant woman: application of a low molecular weight heparinoid [letter]. Thromb Haemost 1986; 55: 301PubMedGoogle Scholar
  59. 59.
    Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70: 554–61PubMedGoogle Scholar
  60. 60.
    Greinacher A, Eckhardt T, Mussmann J. Pregnancy complicated by heparin-associated thrombocytopenia: management by prospectively in vitro selected heparinoid (Org 10172). Thromb Res 1993; 71: 123–6PubMedCrossRefGoogle Scholar
  61. 61.
    Mikhailidis DP, Barradas MA, Mikhailidis AM, et al. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol 1984; 17: 43–8PubMedCrossRefGoogle Scholar
  62. 62.
    Mikhailidis DP, Fonseca VA, Barradas MA, et al. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Clin Pharmacol 1987; 24: 415–24PubMedCrossRefGoogle Scholar
  63. 63.
    Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostas is 1992; 22: 85–91Google Scholar
  64. 64.
    Ramakrishna R, Manoharan A, Kwan YL. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin), and heparinoid, danaparoid (Orgaran). Br J Haematol 1995; 91: 736–8PubMedCrossRefGoogle Scholar
  65. 65.
    Wilde MI, Markham A. Danaparoid: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 6: 903–24CrossRefGoogle Scholar
  66. 66.
    Chong BH, Ismail F, Cade J. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73: 1592–6PubMedGoogle Scholar
  67. 67.
    Rowlings PA, Mansberg R, Rozenberg MC, et al. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin-dependent thrombocytopenia and thrombosis. Aust N Z J Med 1991; 21: 52–4PubMedCrossRefGoogle Scholar
  68. 68.
    Tardy-Poncet B. French experience in the use of Orgaran as an alternative antithrombotic treatment for patients with hepa-rin-induced thrombocytopenia [abstract]. Thromb Haemost 1997; Suppl.: 1825Google Scholar
  69. 69.
    Greinacher A, Vôlpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73–80PubMedCrossRefGoogle Scholar
  70. 70.
    Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100: 587–93PubMedCrossRefGoogle Scholar
  71. 71.
    Eichler P, Greinacher A. Anti-hirudin antibodies induced by recombinand hirudin in the treatment of patients with hepa-rin-induced thrombocytopenia [abstract]. Ann Hematol 1996; 72 Suppl.: A4Google Scholar
  72. 72.
    Schwarz RP. Update on the clinical development of Novastan (Argatroban): a small-molecule direct thrombin inhibitor. In: Zavoico G, editor. Advances in anticoagulant and antithrombotic drugs, IBC Biomedical Library Series. Southborough (MA): International Business Communication Inc., 1996Google Scholar
  73. 73.
    Lewis BE, Walenga JM, Wallis DW. Anticoagulation with Novastan (argatroban) in patients with heparin-induced throm-bocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997; 23: 197–202PubMedCrossRefGoogle Scholar
  74. 74.
    Weitz JL, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385–91PubMedCrossRefGoogle Scholar
  75. 75.
    Willerson JT, Casscells W. Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal? J Am Coll Cardiol 1993; 21: 1048–51PubMedCrossRefGoogle Scholar
  76. 76.
    Wallis DE, Lewis BE, Messmore H. Heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Thromb Hemost 1998; 4: 160–3CrossRefGoogle Scholar
  77. 77.
    Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenis of venous limb gangrene associated with heparin-in-duced thrombocytopenia. Ann Intern Med 1997; 127: 804–12PubMedGoogle Scholar
  78. 78.
    Cairns JA, Kennedy JW, Fuster V. Coronary thrombolysis. Chest 1998; 114: 634–57SCrossRefGoogle Scholar
  79. 79.
    Meneveau N, Bassand JP, Schiele F, et al. Safety of thrombolytic therapy in the elderly patients with massive embolism: a comparison with non-elderly patients. J Am Coll Cardiol 1993; 22: 1075–9PubMedCrossRefGoogle Scholar
  80. 80.
    Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated factors. Chest 1997; 111: 1241–5PubMedCrossRefGoogle Scholar
  81. 81.
    Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis. N Engl J Med 1998; 338: 409–15PubMedCrossRefGoogle Scholar
  82. 82.
    Sobel M, Adelman B, Szentpetery S, et al. Surgical management of heparin-associated thrombocytopenia: strategies in the treatment of venous and arterial thromboembolism. J Vasc Surg 1988; 8: 395–401PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Brigitte Tardy-Poncet
    • 1
  • Bernard Tardy
    • 2
  1. 1.Department of HaematologyUniversity Hospital of St EtienneEtienneFrance
  2. 2.Intensive Care UnitUniversity Hospital of St EtienneEtienneFrance

Personalised recommendations